JP2015509540A5 - - Google Patents

Download PDF

Info

Publication number
JP2015509540A5
JP2015509540A5 JP2014561069A JP2014561069A JP2015509540A5 JP 2015509540 A5 JP2015509540 A5 JP 2015509540A5 JP 2014561069 A JP2014561069 A JP 2014561069A JP 2014561069 A JP2014561069 A JP 2014561069A JP 2015509540 A5 JP2015509540 A5 JP 2015509540A5
Authority
JP
Japan
Prior art keywords
alk
disorder
compound
salt
fak
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014561069A
Other languages
English (en)
Japanese (ja)
Other versions
JP6016953B2 (ja
JP2015509540A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/029304 external-priority patent/WO2013134353A1/en
Publication of JP2015509540A publication Critical patent/JP2015509540A/ja
Publication of JP2015509540A5 publication Critical patent/JP2015509540A5/ja
Application granted granted Critical
Publication of JP6016953B2 publication Critical patent/JP6016953B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014561069A 2012-03-06 2013-03-06 二重のalkおよびfak阻害剤としての縮合二環式2,4−ジアミノピリミジン誘導体 Expired - Fee Related JP6016953B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261607305P 2012-03-06 2012-03-06
US61/607,305 2012-03-06
PCT/US2013/029304 WO2013134353A1 (en) 2012-03-06 2013-03-06 Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016188585A Division JP2017039741A (ja) 2012-03-06 2016-09-27 二重のalkおよびfak阻害剤としての縮合二環式2,4−ジアミノピリミジン誘導体

Publications (3)

Publication Number Publication Date
JP2015509540A JP2015509540A (ja) 2015-03-30
JP2015509540A5 true JP2015509540A5 (https=) 2016-02-25
JP6016953B2 JP6016953B2 (ja) 2016-10-26

Family

ID=47892060

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014561069A Expired - Fee Related JP6016953B2 (ja) 2012-03-06 2013-03-06 二重のalkおよびfak阻害剤としての縮合二環式2,4−ジアミノピリミジン誘導体
JP2016188585A Pending JP2017039741A (ja) 2012-03-06 2016-09-27 二重のalkおよびfak阻害剤としての縮合二環式2,4−ジアミノピリミジン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016188585A Pending JP2017039741A (ja) 2012-03-06 2016-09-27 二重のalkおよびfak阻害剤としての縮合二環式2,4−ジアミノピリミジン誘導体

Country Status (28)

Country Link
US (5) US9132128B2 (https=)
EP (2) EP2822939B1 (https=)
JP (2) JP6016953B2 (https=)
KR (1) KR102068374B1 (https=)
CN (2) CN106166155B (https=)
AU (1) AU2013229995B2 (https=)
CA (1) CA2865420C (https=)
CL (1) CL2014002353A1 (https=)
CY (1) CY1117565T1 (https=)
DK (1) DK2822939T3 (https=)
EA (2) EA033124B1 (https=)
ES (2) ES2681487T3 (https=)
HR (1) HRP20160387T1 (https=)
HU (1) HUE027976T2 (https=)
IL (2) IL234239A (https=)
ME (1) ME02460B (https=)
MX (2) MX372740B (https=)
MY (1) MY177290A (https=)
NZ (1) NZ630251A (https=)
PH (1) PH12014501979B1 (https=)
PL (1) PL2822939T3 (https=)
RS (1) RS54689B1 (https=)
SG (2) SG11201405371PA (https=)
SI (1) SI2822939T1 (https=)
SM (1) SMT201600134B (https=)
UA (1) UA115052C2 (https=)
WO (1) WO2013134353A1 (https=)
ZA (1) ZA201406147B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS54689B1 (sr) * 2012-03-06 2016-08-31 Cephalon, Inc. Spojeni biciklični 2,4- diaminopirimidin derivat kao dualni alk i fak inhibitor
SG11201608303QA (en) 2014-04-04 2016-11-29 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
MX2017008430A (es) * 2014-12-23 2018-03-23 Cephalon Inc Métodos para preparar derivados de 2,4-diaminopirimidina bíclica fusionada.
CA3108236A1 (en) 2018-08-07 2020-02-13 In3Bio Ltd. Methods and compositions for inhibition of egf/egfr pathway in combination with anaplastic lymphoma kinase inhibitors
WO2024178339A2 (en) * 2023-02-23 2024-08-29 The Regents Of The University Of Michigan Methods for treating neuroblastoma with a dual anaplastic lymphoma kinase and focal adhesion kinase inhibitor
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ras相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ras抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1648455A4 (en) 2003-07-23 2009-03-04 Exelixis Inc MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE
PT1660458E (pt) 2003-08-15 2012-04-27 Novartis Ag 2,4-pirimidinodiaminas úteis no tratamento de doenças neoplásicas, desordens inflamatórias e do sistema imunitário
CN1918158B (zh) * 2004-02-14 2011-03-02 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
JP2008502595A (ja) 2004-03-31 2008-01-31 エグゼリクシス, インコーポレイテッド 未分化リンパ腫キナーゼモジュレータおよびその使用方法
ES2622493T3 (es) * 2006-02-24 2017-07-06 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta de JAK
ES2555803T3 (es) 2006-10-23 2016-01-08 Cephalon, Inc. Fusión de derivados bicíclicos 2,4-diaminopirimidina como utilizar inhibidores ALK y c-Met
NZ577197A (en) * 2006-12-08 2011-02-25 Irm Llc Pyrimidine compounds especially 4-phenylamino-2-arylamino-pyrimidine derivatives and compositions as protein kinase inhibitors
CN101678215B (zh) * 2007-04-18 2014-10-01 辉瑞产品公司 用于治疗异常细胞生长的磺酰胺衍生物
ES2575084T3 (es) * 2009-06-10 2016-06-24 Chugai Seiyaku Kabushiki Kaisha Compuesto tetracíclico
RS54689B1 (sr) * 2012-03-06 2016-08-31 Cephalon, Inc. Spojeni biciklični 2,4- diaminopirimidin derivat kao dualni alk i fak inhibitor
KR101446742B1 (ko) * 2012-08-10 2014-10-01 한국화학연구원 N2,n4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
MX2017008430A (es) * 2014-12-23 2018-03-23 Cephalon Inc Métodos para preparar derivados de 2,4-diaminopirimidina bíclica fusionada.

Similar Documents

Publication Publication Date Title
JP2015509540A5 (https=)
JP2015536964A5 (https=)
JP2017504611A5 (https=)
HRP20160387T1 (hr) Spojeni biciklični 2,4-diaminopirimidin derivat kao dualni alk i fak inhibitor
EA201690322A1 (ru) Терапевтически активные соединения и способы их применения
JP2016501221A5 (https=)
PH12015501517A1 (en) Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
PH12015502628B1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
JP2016516808A5 (https=)
EA201590345A1 (ru) Способы лечения рака с использованием 3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
IN2014CN00408A (https=)
JP2016508134A5 (https=)
JP2015508749A5 (https=)
JP2016518337A5 (https=)
JP2013507415A5 (https=)
CA2922684A1 (en) Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases
MX2013012588A (es) Inhibidores de cinasa.
HRP20230477T1 (hr) Spojevi i pripravci uree kao inhibitori smarca2/brm-atpaze
EA201690741A1 (ru) Составы (s)-3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
JP2014509653A5 (https=)
JP2015502926A5 (https=)
MX2016002795A (es) Compuestos de triazolona y usos de los mismos.
RU2018119102A (ru) Терапевтическое средство для лечения рака молочной железы